Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 문영철 | * |
dc.date.accessioned | 2022-08-12T16:31:10Z | - |
dc.date.available | 2022-08-12T16:31:10Z | - |
dc.date.issued | 2022 | * |
dc.identifier.issn | 2152-2650 | * |
dc.identifier.issn | 2152-2669 | * |
dc.identifier.other | OAK-32185 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/262343 | - |
dc.description.abstract | We evaluated the treatment outcome of ruxolitinib, especially focused on RBC TF and anemia in 123 MF patients in a real-world setting. Approximately one-third showed long-term and severe transfusion dependence, respectively. In addition, the presence of MF-related anemia was a risk factor for predicting RBC TF dependency throughout the ruxolitinib treatment. Given these data, patients with = 2 units of RBC TF over eight weeks at the time of ruxolitinib initiation need more supportive care with awareness of the risk of anemia in actual practice. Introduction/Background: Ruxolitinib is an established treatment for myelofibrosis (MF) that has demonstrated clinical benefit by reducing spleen size and debilitating MF-related symptoms. However, despite the efficacy of ruxolitinib, anemia remains a major adverse event that causes dose modification or discontinuation in real-world practice. Additionally, dependence on red blood cell (RBC) transfusion (TF) is common during treatment; therefore, we explored the outcome of ruxolitinib therapy with a primary focus on RBC TF. Patients/Methods: We retrospectively reviewed the medical records of 123 MF patients treated with ruxolitinib between January 2012 and April 2020 at eight academic centers in Korea. Results: At ruxolitinib initiation, 38 patients (30.9%) underwent >= 2 units of RBC TF over 8 weeks. The most common reason for permanent discontinuation was intolerant anemia (10/63, 15.9%). The most common reasons for temporary interruption were nonhematologic toxicity (26/55, 21.1%), anemia (23/55, 18.7%) and thrombocytopenia (13/55, 10.6%). Among the 123 patients in the study, 57 (46.3%), 42 (34.1%), and 40 patients (32.5%) who were receiving or stopped ruxolitinib therapy had a status of RBC TF dependence, long-term RBC TF dependence, or severe RBC TF dependence, respectively. The presence of = 2 units of RBC transfusion over 8 weeks at ruxolitinib initiation was an independent risk factor for persistent RBC TF dependence. Conclusion: The requirement for RBC TF is commonly encountered during treatment of MF with ruxolitinib, particularly among those with pre-existing = 2 units of RBC TF over 8 weeks. For those patients, overcoming the barrier of maintenance TF is demanding. | * |
dc.language | English | * |
dc.publisher | CIG MEDIA GROUP, LP | * |
dc.subject | Anemia | * |
dc.subject | Red Blood Cell Transfusion | * |
dc.subject | Myelofibrosis | * |
dc.subject | Ruxolitinib | * |
dc.subject | Transfusion | * |
dc.title | Real-World Outcomes of Ruxolitinib in Patients With Myelofibrosis Focusing on Red Blood Cell Transfusion: A Multicenter Study From the MPN Working Party of the Korean Society of Hematology | * |
dc.type | Article | * |
dc.relation.issue | 10 | * |
dc.relation.volume | 22 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | E931 | * |
dc.relation.lastpage | E937 | * |
dc.relation.journaltitle | CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | * |
dc.identifier.doi | 10.1016/j.clml.2022.06.008 | * |
dc.identifier.wosid | WOS:000903822700007 | * |
dc.identifier.scopusid | 2-s2.0-85134617475 | * |
dc.author.google | Jung, Eun Hee | * |
dc.author.google | Hong, Junshik | * |
dc.author.google | Kim, Sung-Yong | * |
dc.author.google | Park, Young | * |
dc.author.google | Yuh, Young Jin | * |
dc.author.google | Mun, Yeung-Chul | * |
dc.author.google | Lee, Won-Sik | * |
dc.author.google | Park, Sung-Kyu | * |
dc.author.google | Bang, Soo Mee | * |
dc.contributor.scopusid | 문영철(7003363716) | * |
dc.date.modifydate | 20240422115947 | * |